{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T02:18:02Z","timestamp":1787883482482,"version":"build-2784847793"},"reference-count":179,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.cpcardiol.2025.103081","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T19:28:13Z","timestamp":1748633293000},"page":"103081","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Early prescription of SGLT2i for acute patient care: from current evidence to future directions"],"prefix":"10.1016","volume":"50","author":[{"given":"Fabrizio","family":"Ricci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Saraullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9303-7790","authenticated-orcid":false,"given":"Andrea","family":"Boccatonda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sorella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Cipollone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Simeone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Gallina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Santilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cipollone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damiano","family":"D\u2019Ardes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.cpcardiol.2025.103081_bib0001","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCRESAHA.117.311586","article-title":"Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity","volume":"122","author":"Jia","year":"2018","journal-title":"Circ Res"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103081_bib0002","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12933-018-0728-6","article-title":"Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017","volume":"17","author":"Einarson","year":"2018","journal-title":"Cardiovasc Diabetol"},{"issue":"11","key":"10.1016\/j.cpcardiol.2025.103081_bib0003","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 Diabetes, 2022. A consensus report by the american diabetes association (ada) and the european association for the study of diabetes (EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103081_bib0004","doi-asserted-by":"crossref","first-page":"69","DOI":"10.4158\/CS-2018-0535","article-title":"Consensus statement by the American Association of clinical endocrinologists and American college of endocrinology on the comprehensive type 2 diabetes management Algorithm - 2019 executive summary","volume":"25","author":"Garber","year":"2019","journal-title":"Endocr Pract"},{"issue":"4","key":"10.1016\/j.cpcardiol.2025.103081_bib0005","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.numecd.2022.01.027","article-title":"Italian guidelines for the treatment of type 2 diabetes","volume":"32","author":"Mannucci","year":"2022","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"15","key":"10.1016\/j.cpcardiol.2025.103081_bib0006","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.cpcardiol.2025.103081_bib0007","first-page":"2099","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.cpcardiol.2025.103081_bib0008","first-page":"1881","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes. Reply","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.cpcardiol.2025.103081_bib0009","first-page":"1094","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"374","author":"Zinman","year":"2016","journal-title":"N Engl J Med"},{"issue":"10166","key":"10.1016\/j.cpcardiol.2025.103081_bib0010","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.cpcardiol.2025.103081_bib0011","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1093\/eurheartj\/ehad857","article-title":"Correction to: 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC)","volume":"45","year":"2024","journal-title":"Eur Heart J"},{"issue":"21","key":"10.1016\/j.cpcardiol.2025.103081_bib0012","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.cpcardiol.2025.103081_bib0013","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.cpcardiol.2025.103081_bib0014","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1093\/eurheartj\/ehab798","article-title":"Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction","volume":"43","author":"Butler","year":"2022","journal-title":"Eur Heart J"},{"issue":"15","key":"10.1016\/j.cpcardiol.2025.103081_bib0015","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with Empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.cpcardiol.2025.103081_bib0016","doi-asserted-by":"crossref","first-page":"F1269","DOI":"10.1152\/ajprenal.00543.2015","article-title":"Predicted consequences of diabetes and SGLT inhibition on transport and oxygen consumption along a rat nephron","volume":"310","author":"Layton","year":"2016","journal-title":"Am J Physiol Renal Physiol"},{"issue":"3","key":"10.1016\/j.cpcardiol.2025.103081_bib0017","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/969","article-title":"Renal and intestinal absorptive defects in mice lacking the NHE3 Na+\/H+ exchanger","volume":"19","author":"Schultheis","year":"1998","journal-title":"Nat Genet"},{"issue":"12","key":"10.1016\/j.cpcardiol.2025.103081_bib0018","doi-asserted-by":"crossref","first-page":"F1343","DOI":"10.1152\/ajprenal.00007.2015","article-title":"Modeling oxygen consumption in the proximal tubule: effects of NHE and SGLT2 inhibition","volume":"308","author":"Layton","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"issue":"6","key":"10.1016\/j.cpcardiol.2025.103081_bib0019","first-page":"F914","article-title":"HCO-3 reabsorption in renal collecting duct of NHE-3-deficient mouse: a compensatory response","volume":"276","author":"Nakamura","year":"1999","journal-title":"Am J Physiol"},{"issue":"48","key":"10.1016\/j.cpcardiol.2025.103081_bib0020","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1093\/eurheartj\/ehac495","article-title":"Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme","volume":"43","author":"Zannad","year":"2022","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103081_bib0021","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/BF00381513","article-title":"Acetazolamide inhibition of basolateral Cl-\/HCO3- exchange in rabbit renal proximal tubule S3 segment","volume":"422","author":"Seki","year":"1992","journal-title":"Pflugers Arch"},{"issue":"11","key":"10.1016\/j.cpcardiol.2025.103081_bib0022","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1161\/HYPERTENSIONAHA.122.19888","article-title":"Role of uromodulin in salt-sensitive hypertension","volume":"79","author":"Mary","year":"2022","journal-title":"Hypertension"},{"issue":"13","key":"10.1016\/j.cpcardiol.2025.103081_bib0023","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.016173","article-title":"Acute and chronic effects of SGLT2 inhibitor Empagliflozin on renal oxygenation and blood pressure control in nondiabetic normotensive subjects: a randomized, placebo-controlled trial","volume":"9","author":"Zanchi","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103081_bib0024","doi-asserted-by":"crossref","first-page":"R75","DOI":"10.1152\/ajpregu.00357.2011","article-title":"Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat","volume":"302","author":"Thomson","year":"2012","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103081_bib0025","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.kint.2019.09.013","article-title":"The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial","volume":"97","author":"van Bommel","year":"2020","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.cpcardiol.2025.103081_bib0026","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1111\/dom.14677","article-title":"The differential effects of ertugliflozin on glucosuria and natriuresis biomarkers: prespecified analyses from VERTIS CV","volume":"24","author":"Cherney","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.cpcardiol.2025.103081_bib0027","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/ki.1980.50","article-title":"Set point for sodium homeostasis: surfeit, deficit, and their implications","volume":"17","author":"Hollenberg","year":"1980","journal-title":"Kidney Int"},{"issue":"15","key":"10.1016\/j.cpcardiol.2025.103081_bib0028","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.jacc.2024.02.028","article-title":"SGLT2 Inhibition: neither a diuretic nor a natriuretic","volume":"83","author":"Packer","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"10.1016\/j.cpcardiol.2025.103081_bib0029","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.jacc.2024.02.020","article-title":"Water conservation overrides osmotic diuresis during SGLT2 inhibition in patients with heart failure","volume":"83","author":"Marton","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.cpcardiol.2025.103081_bib0030","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jchf.2022.01.019","article-title":"Relationship of Dapagliflozin with serum sodium: findings from the DAPA-HF trial","volume":"10","author":"Yeoh","year":"2022","journal-title":"JACC Heart Fail"},{"issue":"4","key":"10.1016\/j.cpcardiol.2025.103081_bib0031","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jacc.2019.11.031","article-title":"Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review","volume":"75","author":"Zelniker","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"10.1016\/j.cpcardiol.2025.103081_bib0032","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.122.061732","article-title":"Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling\/autophagy hypothesis","volume":"146","author":"Packer","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2025.103081_bib0033","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev-physiol-021317-121427","article-title":"The role of autophagy in the heart","volume":"80","author":"Sciarretta","year":"2018","journal-title":"Annu Rev Physiol"},{"issue":"7","key":"10.1016\/j.cpcardiol.2025.103081_bib0034","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41569-022-00824-4","article-title":"SGLT2 inhibitors: role in protective reprogramming of cardiac nutrient transport and metabolism","volume":"20","author":"Packer","year":"2023","journal-title":"Nat Rev Cardiol"},{"issue":"4","key":"10.1016\/j.cpcardiol.2025.103081_bib0035","first-page":"e38","article-title":"Heart Disease and Stroke statistics-2016 update: a report from the American Heart Association","volume":"133","author":"Mozaffarian","year":"2016","journal-title":"Circulation."},{"issue":"10","key":"10.1016\/j.cpcardiol.2025.103081_bib0036","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41569-020-0379-7","article-title":"Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment","volume":"17","author":"Boorsma","year":"2020","journal-title":"Nat Rev Cardiol"},{"issue":"3","key":"10.1016\/j.cpcardiol.2025.103081_bib0037","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jacc.2021.05.021","article-title":"Pathophysiology of the lymphatic system in patients with heart failure: JACC State-of-the-art review","volume":"78","author":"Itkin","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2025.103081_bib0038","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ijcard.2018.01.067","article-title":"Prevalence, predictors and clinical outcome of residual congestion in acute decompensated heart failure","volume":"258","author":"Rubio-Gracia","year":"2018","journal-title":"Int J Cardiol"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103081_bib0039","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/eurheartj\/ehac530","article-title":"Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial","volume":"44","author":"Biegus","year":"2023","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.cpcardiol.2025.103081_bib0040","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1093\/eurheartj\/ehab798","article-title":"Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction","volume":"43","author":"Butler","year":"2021","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.cpcardiol.2025.103081_bib0041","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1038\/s41591-022-01971-4","article-title":"Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER","volume":"28","author":"Jhund","year":"2022","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.cpcardiol.2025.103081_bib0042","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1161\/CIRCULATIONAHA.123.064346","article-title":"Critical analysis of the effects of SGLT2 inhibitors on renal tubular sodium, water and chloride homeostasis and their role in influencing heart failure outcomes","volume":"148","author":"Packer","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2025.103081_bib0043","article-title":"Effects of sodium-glucose cotransporter 2 inhibitors on water and sodium metabolism","volume":"13","author":"Tang","year":"2022","journal-title":"Front Pharmacol"},{"issue":"2","key":"10.1016\/j.cpcardiol.2025.103081_bib0044","doi-asserted-by":"crossref","first-page":"440","DOI":"10.2337\/dc20-2604","article-title":"Natriuretic effect of two weeks of Dapagliflozin treatment in patients with type 2 diabetes and preserved kidney function during standardized sodium intake: results of the DAPASALT trial","volume":"44","author":"Scholtes","year":"2021","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103081_bib0045","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s12933-023-01946-w","article-title":"Lack of durable natriuresis and objective decongestion following SGLT2 inhibition in randomized controlled trials of patients with heart failure","volume":"22","author":"Packer","year":"2023","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"10.1016\/j.cpcardiol.2025.103081_bib0046","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/ejhf.1713","article-title":"Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF)","volume":"22","author":"Damman","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"10.1016\/j.cpcardiol.2025.103081_bib0047","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1161\/CIRCULATIONAHA.122.059038","article-title":"Effects of early Empagliflozin initiation on Diuresis and kidney function in patients with acute decompensated heart failure (EMPAG-HF)","volume":"146","author":"Schulze","year":"2022","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.cpcardiol.2025.103081_bib0048","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.cpcardiol.2025.103081_bib0049","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.007048","article-title":"Effect of Empagliflozin as an add-on therapy on decongestion and renal function in patients with diabetes hospitalized for acute decompensated heart failure: a prospective randomized controlled study","volume":"14","author":"Tamaki","year":"2021","journal-title":"Circ Heart Fail"},{"issue":"5","key":"10.1016\/j.cpcardiol.2025.103081_bib0050","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1253\/circrep.CR-22-0118","article-title":"Early initiation of sodium-glucose cotransporter 2 inhibitor leads to a shorter hospital stay in patients with acute decompensated heart failure","volume":"5","author":"Matsukawa","year":"2023","journal-title":"Circ Rep"},{"issue":"4","key":"10.1016\/j.cpcardiol.2025.103081_bib0051","doi-asserted-by":"crossref","first-page":"81","DOI":"10.31083\/j.fbl2804081","article-title":"Sodium-glucose cotransporter 2 inhibitors first strategy improve decongestion in patients with symptomatic heart failure and reduced ejection fraction when compared to angiotensin receptor neprilysin inhibitor first strategy","volume":"28","author":"Lee","year":"2023","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103081_bib0052","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/ehf2.14597","article-title":"Sodium-glucose co-transporter 2 inhibitors in acute heart failure: real-world prescription trends and outcomes analysis","volume":"11","author":"Mizobuchi","year":"2024","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.cpcardiol.2025.103081_bib0053","article-title":"Long-term efficacy of SGLT2 inhibitors for elderly patients with acute decompensated heart failure: the OASIS-HF study","author":"Amioka","year":"2024","journal-title":"ESC Heart Fail"},{"issue":"6","key":"10.1016\/j.cpcardiol.2025.103081_bib0054","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25063122","article-title":"The role of sodium-glucose Co-transporter-2 inhibitors on diuretic resistance in heart failure","volume":"25","author":"Stachteas","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"31","key":"10.1016\/j.cpcardiol.2025.103081_bib0055","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1093\/eurheartj\/ehad341","article-title":"Dapagliflozin vs. metolazone in heart failure resistant to loop diuretics","volume":"44","author":"Yeoh","year":"2023","journal-title":"Eur Heart J"},{"issue":"31","key":"10.1016\/j.cpcardiol.2025.103081_bib0056","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1093\/eurheartj\/ehad341","article-title":"Dapagliflozin vs. metolazone in heart failure resistant to loop diuretics","volume":"44","author":"Yeoh","year":"2023","journal-title":"Eur Heart J"},{"issue":"23","key":"10.1016\/j.cpcardiol.2025.103081_bib0057","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1016\/j.jacc.2024.03.405","article-title":"Left ventricular function, congestion, and effect of Empagliflozin on heart failure risk after myocardial infarction","volume":"83","author":"Udell","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103081_bib0058","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1186\/s12933-024-02312-0","article-title":"The potential anti-arrhythmic effect of SGLT2 inhibitors","volume":"23","author":"Duan","year":"2024","journal-title":"Cardiovasc Diabetol"},{"issue":"20","key":"10.1016\/j.cpcardiol.2025.103081_bib0059","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1016\/j.jacc.2022.03.353","article-title":"Sodium glucose cotransporter-2 inhibition for acute myocardial infarction: JACC review topic of the week","volume":"79","author":"Udell","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"10.1016\/j.cpcardiol.2025.103081_bib0060","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/j.jacc.2019.01.056","article-title":"Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics","volume":"73","author":"Santos-Gallego","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"Supplement_1","key":"10.1016\/j.cpcardiol.2025.103081_bib0061","doi-asserted-by":"crossref","first-page":"i84","DOI":"10.1093\/eurheartjsupp\/suae008","article-title":"The role of sodium\u2013glucose co-transporter 2 inhibitors in myocardial infarction: available evidence and future perspectives","volume":"26","author":"Tavecchia","year":"2024","journal-title":"European Heart Journal Supplements"},{"issue":"3","key":"10.1016\/j.cpcardiol.2025.103081_bib0062","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1161\/CIRCULATIONAHA.122.061688","article-title":"Sodium glucose cotransporter-2 inhibitor Empagliflozin reduces infarct size independently of Sodium glucose cotransporter-2","volume":"147","author":"Chen","year":"2023","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103081_bib0063","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s12933-021-01392-6","article-title":"Empagliflozin protects the heart against ischemia\/reperfusion-induced sudden cardiac death","volume":"20","author":"Hu","year":"2021","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103081_bib0064","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12933-020-01127-z","article-title":"Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial","volume":"19","author":"Shimizu","year":"2020","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103081_bib0065","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12933-023-01758-y","article-title":"Impact of chronic GLP-1 RA and SGLT-2I therapy on in-hospital outcome of diabetic patients with acute myocardial infarction","volume":"22","author":"Trombara","year":"2023","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103081_bib0066","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12933-022-01506-8","article-title":"Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry","volume":"21","author":"Paolisso","year":"2022","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"10.1016\/j.cpcardiol.2025.103081_bib0067","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s00228-023-03495-3","article-title":"Dapagliflozin reduces risk of heart failure rehospitalization in diabetic acute myocardial infarction patients: a propensity score-matched analysis","volume":"79","author":"Mao","year":"2023","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"41","key":"10.1016\/j.cpcardiol.2025.103081_bib0068","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.1093\/eurheartj\/ehac494","article-title":"Empagliflozin in acute myocardial infarction: the EMMY trial","volume":"43","author":"von Lewinski","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2025.103081_bib0069","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ijcard.2023.03.002","article-title":"Impact of dapagliflozin on cardiac function following anterior myocardial infarction in non-diabetic patients - DACAMI (a randomized controlled clinical trial)","volume":"379","author":"Dayem","year":"2023","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cpcardiol.2025.103081_bib0070","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ahj.2023.08.008","article-title":"Rationale and design of the DAPA-MI trial: dapagliflozin in patients without diabetes mellitus with acute myocardial infarction","volume":"266","author":"James","year":"2023","journal-title":"Am Heart J"},{"issue":"2","key":"10.1016\/j.cpcardiol.2025.103081_bib0071","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300286","article-title":"Dapagliflozin in myocardial infarction without diabetes or heart failure","volume":"3","author":"James","year":"2024","journal-title":"NEJM Evid"},{"issue":"2","key":"10.1016\/j.cpcardiol.2025.103081_bib0072","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/ehjcvp\/pvad099","article-title":"SGLT2 inhibitors in acute myocardial infarction: what can we learn from the DAPA-MI trial? More news from American Heart Association Scientific Meeting","volume":"10","author":"Kato","year":"2023","journal-title":"Eur Heart J - Cardiovascul Pharmacotherapy"},{"issue":"21","key":"10.1016\/j.cpcardiol.2025.103081_bib0073","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1161\/CIRCULATIONAHA.124.069217","article-title":"Effect of Empagliflozin on heart failure outcomes after acute myocardial infarction: insights from the EMPACT-MI trial","volume":"149","author":"Hernandez","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2025.103081_bib0074","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2024.1383669","article-title":"Sodium-glucose cotransporter-2 inhibitors improve cardiovascular outcomes post-acute coronary syndrome complicated by acute heart failure","volume":"11","author":"Rahhal","year":"2024","journal-title":"Front Cardiovasc Med"},{"issue":"14","key":"10.1016\/j.cpcardiol.2025.103081_bib0075","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.027824","article-title":"Sodium-glucose cotransporter-2 inhibitors after acute myocardial infarction in patients with type 2 diabetes: a population-based investigation","volume":"12","author":"Kwon","year":"2023","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103081_bib0076","doi-asserted-by":"crossref","first-page":"29","DOI":"10.33963\/v.kp.98260","article-title":"Potential renoprotective effect of SGLT2 inhibitors against contrast-induced AKI in diabetic STEMI patients undergoing primary PCI","volume":"82","author":"K\u00fclt\u00fcrsay","year":"2024","journal-title":"Kardiol Pol"},{"key":"10.1016\/j.cpcardiol.2025.103081_bib0077","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2023.110766","article-title":"Impact of SGLT2-inhibitors on contrast-induced acute kidney injury in diabetic patients with acute myocardial infarction with and without chronic kidney disease: insight from SGLT2-I AMI PROTECT registry","volume":"202","author":"Paolisso","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.cpcardiol.2025.103081_bib0078","doi-asserted-by":"crossref","DOI":"10.1007\/s00228-024-03623-7","article-title":"Association of SGLT2 inhibitor dapagliflozin with risks of acute kidney injury and all-cause mortality in acute myocardial infarction patients","author":"Cai","year":"2024","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.cpcardiol.2025.103081_bib0079","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.918167","article-title":"Contrast-induced acute kidney injury in patients on SGLT2 inhibitors undergoing percutaneous coronary interventions: a propensity-matched analysis","volume":"9","author":"Hua","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103081_bib0080","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s12933-023-01950-0","article-title":"Empagliflozin improves insulin sensitivity in patients with recent acute coronary syndrome and newly detected dysglycaemia","volume":"22","author":"Fortin","year":"2023","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"10.1016\/j.cpcardiol.2025.103081_bib0081","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1093\/ehjci\/jey101","article-title":"Intramyocardial haemorrhage and prognosis after ST-elevation myocardial infarction","volume":"20","author":"Reinstadler","year":"2019","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"21","key":"10.1016\/j.cpcardiol.2025.103081_bib0082","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1016\/j.jacc.2024.03.408","article-title":"Clinical outcomes associated with various microvascular injury patterns identified by CMR after STEMI","volume":"83","author":"Lechner","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103081_bib0083","doi-asserted-by":"crossref","first-page":"6394","DOI":"10.1038\/s41467-022-33776-x","article-title":"Intramyocardial hemorrhage drives fatty degeneration of infarcted myocardium","volume":"13","author":"Cokic","year":"2022","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103081_bib0084","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12916-023-02781-2","article-title":"SGLT-2 inhibitors and in-stent restenosis-related events after acute myocardial infarction: an observational study in patients with type 2 diabetes","volume":"21","author":"Marfella","year":"2023","journal-title":"BMC Med"},{"issue":"10","key":"10.1016\/j.cpcardiol.2025.103081_bib0085","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1007\/s00380-020-01621-0","article-title":"Empagliflozin attenuates neointimal hyperplasia after drug-eluting-stent implantation in patients with type 2 diabetes","volume":"35","author":"Hashikata","year":"2020","journal-title":"Heart Vessels"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103081_bib0086","doi-asserted-by":"crossref","first-page":"9364","DOI":"10.1038\/s41598-021-88593-x","article-title":"Effects of stent generation on clinical outcomes after acute myocardial infarction compared between prediabetes and diabetes patients","volume":"11","author":"Kim","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.cpcardiol.2025.103081_bib0087","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.1040649","article-title":"Editorial: clinical prospective of SGLT2 inhibitors in atherosclerosis","volume":"9","author":"Capuano","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.cpcardiol.2025.103081_bib0088","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.1008922","article-title":"Anti-inflammatory role of SGLT2 inhibitors as part of their anti-atherosclerotic activity: data from basic science and clinical trials","volume":"9","author":"Scisciola","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.cpcardiol.2025.103081_bib0089","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101337","article-title":"Sodium-glucose co-transporter2 expression and inflammatory activity in diabetic atherosclerotic plaques: effects of sodium-glucose co-transporter2 inhibitor treatment","volume":"54","author":"D'Onofrio","year":"2021","journal-title":"Mol Metab"},{"key":"10.1016\/j.cpcardiol.2025.103081_bib0090","article-title":"SGLT2 inhibitor improves the prognosis of patients with coronary heart disease and prevents in-stent restenosis","volume":"10","author":"Zhang","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.cpcardiol.2025.103081_bib0091","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.751214","article-title":"The role of SGLT2 inhibitors in atherosclerosis: a narrative mini-review","volume":"12","author":"Pahud de Mortanges","year":"2021","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103081_bib0092","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12933-023-01814-7","article-title":"SGLT2-inhibitors effects on the coronary fibrous cap thickness and MACEs in diabetic patients with inducible myocardial ischemia and multi vessels non-obstructive coronary artery stenosis","volume":"22","author":"Sardu","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.cpcardiol.2025.103081_bib0093","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.amjcard.2023.12.056","article-title":"Sodium-glucose cotransporter-2 inhibitors stabilize coronary plaques in acute coronary syndrome with Diabetes mellitus","volume":"214","author":"Kurozumi","year":"2024","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.1016\/j.cpcardiol.2025.103081_bib0094","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/dom.14854","article-title":"Incident heart failure, arrhythmias and cardiovascular outcomes with sodium-glucose cotransporter 2 (SGLT2) inhibitor use in patients with diabetes: insights from a global federated electronic medical record database","volume":"25","author":"Fawzy","year":"2023","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"10.1016\/j.cpcardiol.2025.103081_bib0095","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.119.007351","article-title":"Atrial fibrillation and diabetes mellitus: can we modify stroke risk through glycemic control?","volume":"12","author":"Ugowe","year":"2019","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103081_bib0096","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s12933-020-01162-w","article-title":"The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors","volume":"19","author":"Ling","year":"2020","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"10.1016\/j.cpcardiol.2025.103081_bib0097","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1046\/j.1540-8167.2002.00399.x","article-title":"Atrial fibrillation and congestive heart failure: specific considerations at the intersection of two common and important cardiac disease sets","volume":"13","author":"Ehrlich","year":"2002","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"18","key":"10.1016\/j.cpcardiol.2025.103081_bib0098","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1161\/CIRCULATIONAHA.108.821306","article-title":"Atrial fibrillation and heart failure: treatment considerations for a dual epidemic","volume":"119","author":"Anter","year":"2009","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.cpcardiol.2025.103081_bib0099","doi-asserted-by":"crossref","first-page":"45","DOI":"10.4239\/wjd.v7.i3.45","article-title":"Role of diabetes in heart rhythm disorders","volume":"7","author":"Koektuerk","year":"2016","journal-title":"World J Diabetes"},{"issue":"4","key":"10.1016\/j.cpcardiol.2025.103081_bib0100","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.122.015176","article-title":"Empagliflozin improves left atrial strain in patients with type 2 diabetes: data from a randomized, placebo-controlled study","volume":"16","author":"Thiele","year":"2023","journal-title":"Circ Cardiovasc Imaging"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103081_bib0101","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12933-019-0964-4","article-title":"Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet\/streptozotocin-induced diabetic rats","volume":"18","author":"Shao","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.cpcardiol.2025.103081_bib0102","doi-asserted-by":"crossref","first-page":"912","DOI":"10.3389\/fphys.2020.00912","article-title":"Sodium-glucose cotransporter 2 inhibitors potentially prevent atrial fibrillation by ameliorating ion handling and mitochondrial dysfunction","volume":"11","author":"Peng","year":"2020","journal-title":"Front Physiol"},{"issue":"4","key":"10.1016\/j.cpcardiol.2025.103081_bib0103","first-page":"232","article-title":"SGLT2i alleviates epicardial adipose tissue inflammation by modulating ketone body-glyceraldehyde-3-phosphate dehydrogenase malonylation pathway","volume":"24","author":"Li","year":"2023","journal-title":"J Cardiovasc Med (Hagerstown)"},{"issue":"12","key":"10.1016\/j.cpcardiol.2025.103081_bib0104","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.5551\/jat.48009","article-title":"The effect of Dapagliflozin treatment on epicardial adipose tissue volume and P-wave indices: an ad-hoc analysis of The previous randomized clinical trial","volume":"27","author":"Sato","year":"2020","journal-title":"J Atheroscler Thromb"},{"issue":"2","key":"10.1016\/j.cpcardiol.2025.103081_bib0105","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jdiacomp.2017.09.009","article-title":"Severe hypoglycemia is a risk factor for atrial fibrillation in type 2 diabetes mellitus: nationwide population-based cohort study","volume":"32","author":"Ko","year":"2018","journal-title":"J Diabetes Complications"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103081_bib0106","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00395-023-01022-0","article-title":"Acute antiarrhythmic effects of SGLT2 inhibitors\u2013dapagliflozin lowers the excitability of atrial cardiomyocytes","volume":"119","author":"Paasche","year":"2024","journal-title":"Basic Res Cardiol"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103081_bib0107","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s12933-022-01552-2","article-title":"Putative protective effects of sodium-glucose cotransporter 2 inhibitors on atrial fibrillation through risk factor modulation and off-target actions: potential mechanisms and future directions","volume":"21","author":"Shetty","year":"2022","journal-title":"Cardiovasc Diabetol"},{"issue":"10","key":"10.1016\/j.cpcardiol.2025.103081_bib0108","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/j.jacep.2023.06.017","article-title":"SGLT2 Inhibitors and catheter ablation for atrial fibrillation: go with the flow-zin?","volume":"9","author":"Calvert","year":"2023","journal-title":"JACC Clin Electrophysiol"},{"issue":"18","key":"10.1016\/j.cpcardiol.2025.103081_bib0109","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13185408","article-title":"The role of sodium glucose Co-transporter 2 inhibitors in atrial fibrillation: a comprehensive review","volume":"13","author":"Stachteas","year":"2024","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103081_bib0110","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s42444-024-00109-6","article-title":"SGLT2 inhibitors and the cardiac rhythm: unraveling the connections","volume":"25","author":"Paul","year":"2024","journal-title":"Int J Arrhythmia"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103081_bib0111","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12933-023-01756-0","article-title":"Empagliflozin suppressed cardiac fibrogenesis through sodium-hydrogen exchanger inhibition and modulation of the calcium homeostasis","volume":"22","author":"Chung","year":"2023","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"10.1016\/j.cpcardiol.2025.103081_bib0112","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/ehf2.12336","article-title":"Empagliflozin reduces Ca\/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes","volume":"5","author":"Mustroph","year":"2018","journal-title":"ESC Heart Fail"},{"issue":"15","key":"10.1016\/j.cpcardiol.2025.103081_bib0113","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1161\/CIRCULATIONAHA.119.044183","article-title":"Effect of Dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus: insights from the DECLARE-TIMI 58 trial","volume":"141","author":"Zelniker","year":"2020","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.cpcardiol.2025.103081_bib0114","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/ejhf.2381","article-title":"Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF","volume":"24","author":"Butt","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"10.1016\/j.cpcardiol.2025.103081_bib0115","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1111\/dom.14772","article-title":"Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: a secondary analysis from the CANVAS Program and CREDENCE trial and meta-analysis","volume":"24","author":"Li","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103081_bib0116","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12933-024-02137-x","article-title":"Effect of SGLT-2 inhibitors on arrhythmia events: insight from an updated secondary analysis of\u2009>\u200980,000 patients (the SGLT2i\u2014arrhythmias and Sudden Cardiac Death)","volume":"23","author":"Liao","year":"2024","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"10.1016\/j.cpcardiol.2025.103081_bib0117","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1093\/ehjcvp\/pvae022","article-title":"Sodium-glucose cotransporter-2 inhibitors and the risk of atrial fibrillation in patients with type 2 diabetes: a population-based cohort study","volume":"10","author":"Eroglu","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103081_bib0118","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12933-021-01243-4","article-title":"SGLT-2 inhibitors and atrial fibrillation in the food and drug administration adverse event reporting system","volume":"20","author":"Bonora","year":"2021","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"10.1016\/j.cpcardiol.2025.103081_bib0119","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2337\/dc22-0714","article-title":"Sodium-glucose cotransporter 2 inhibitor treatment and risk of atrial fibrillation: scandinavian cohort study","volume":"46","author":"Engstr\u00f6m","year":"2023","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.cpcardiol.2025.103081_bib0120","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s10557-022-07319-x","article-title":"Comparison of sodium-glucose cotransporter-2 inhibitor and dipeptidyl peptidase-4 inhibitor on the risks of new-onset atrial fibrillation, stroke and mortality in diabetic patients: a propensity score-matched study in Hong Kong","volume":"37","author":"Lee","year":"2023","journal-title":"Cardiovasc Drugs Ther"},{"issue":"3","key":"10.1016\/j.cpcardiol.2025.103081_bib0121","doi-asserted-by":"crossref","DOI":"10.1093\/europace\/euae054","article-title":"Association between sodium\u2013glucose cotransporter-2 inhibitors and arrhythmic outcomes in patients with diabetes and pre-existing atrial fibrillation","volume":"26","author":"Fichadiya","year":"2024","journal-title":"EP Europace"},{"issue":"10","key":"10.1016\/j.cpcardiol.2025.103081_bib0122","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.027764","article-title":"Sodium-glucose cotransporter-2 inhibitor prevents stroke in patients with diabetes and atrial fibrillation","volume":"12","author":"Chang","year":"2023","journal-title":"J Am Heart Assoc"},{"issue":"8","key":"10.1016\/j.cpcardiol.2025.103081_bib0123","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12082814","article-title":"Cerebrovascular, cognitive and cardiac benefits of SGLT2 inhibitors therapy in patients with atrial fibrillation and type 2 diabetes mellitus: results from a global federated health network analysis","volume":"12","author":"Proietti","year":"2023","journal-title":"J Clin Med"},{"issue":"4","key":"10.1016\/j.cpcardiol.2025.103081_bib0124","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s10741-022-10281-3","article-title":"Association between sodium-glucose cotransporter-2 inhibitors and incident atrial fibrillation\/atrial flutter in heart failure patients with reduced ejection fraction: a meta-analysis of randomized controlled trials","volume":"28","author":"Sfairopoulos","year":"2023","journal-title":"Heart Fail Rev"},{"issue":"7","key":"10.1016\/j.cpcardiol.2025.103081_bib0125","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/ejhf.2861","article-title":"Empagliflozin in heart failure with preserved ejection fraction with and without atrial fibrillation","volume":"25","author":"Filippatos","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2025.103081_bib0126","article-title":"Meta-analysis addressing the impact of sodium-glucose Co-transporter-2 inhibitors on the risk for atrial fibrillation among individuals with heart failure with preserved ejection fraction","volume":"15","author":"Patoulias","year":"2022","journal-title":"Int J Cardiol Cardiovasc Risk Prev"},{"issue":"12","key":"10.1016\/j.cpcardiol.2025.103081_bib0127","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1111\/pace.14374","article-title":"Early rhythm-control ablation therapy to prevent atrial fibrillation recurrences: insights from the CHARISMA Registry","volume":"44","author":"Solimene","year":"2021","journal-title":"Pacing Clin Electrophysiol"},{"issue":"11","key":"10.1016\/j.cpcardiol.2025.103081_bib0128","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.jacep.2022.08.004","article-title":"Efficacy of sodium-glucose cotransporter 2 inhibitors on outcomes after catheter ablation for atrial fibrillation","volume":"8","author":"Kishima","year":"2022","journal-title":"JACC Clin Electrophysiol"},{"issue":"10","key":"10.1016\/j.cpcardiol.2025.103081_bib0129","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1016\/j.jacep.2023.06.008","article-title":"Impact of SGLT2 inhibitors on AF recurrence after catheter ablation in patients with type 2 diabetes","volume":"9","author":"Abu-Qaoud","year":"2023","journal-title":"JACC Clin Electrophysiol"},{"issue":"5","key":"10.1016\/j.cpcardiol.2025.103081_bib0130","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s40256-024-00661-5","article-title":"Impact of SGLT2 inhibitors on atrial fibrillation recurrence after catheter ablation in type 2 diabetes mellitus: a meta-analysis of reconstructed Kaplan\u2013Meier curves with trial sequential analysis","volume":"24","author":"Soliman","year":"2024","journal-title":"American Journal of Cardiovascular Drugs"},{"issue":"24","key":"10.1016\/j.cpcardiol.2025.103081_bib0131","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.031269","article-title":"Impact of sodium-glucose cotransporter 2 inhibitor on recurrence after catheter ablation for atrial fibrillation in patients with diabetes: a propensity-score matching study and meta-analysis","volume":"12","author":"Zhao","year":"2023","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103081_bib0132","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s10557-022-07368-2","article-title":"Effect of Dapagliflozin on the outcome of radiofrequency catheter ablation in patients with type 2 diabetes mellitus and atrial fibrillation","volume":"38","author":"Luo","year":"2024","journal-title":"Cardiovasc Drugs Therapy"},{"key":"10.1016\/j.cpcardiol.2025.103081_bib0133","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2024.132359","article-title":"Effectiveness of sodium-glucose co-transporter 2 inhibitors on atrial fibrillation recurrence after catheter ablation: a systemic review and meta-analysis","volume":"413","author":"Zhang","year":"2024","journal-title":"Int J Cardiol"},{"issue":"9","key":"10.1016\/j.cpcardiol.2025.103081_bib0134","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1111\/jce.16369","article-title":"Relationship between sodium-glucose cotransporter 2 inhibitors and atrial fibrillation recurrence after pulmonary vein isolation in patients with type 2 diabetes and persistent atrial fibrillation","volume":"35","author":"Qi","year":"2024","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.cpcardiol.2025.103081_bib0135","article-title":"Impact of sodium-glucose cotransporter 2 inhibitor on recurrence and cardiovascular outcomes after catheter ablation for atrial fibrillation in patients with heart failure","author":"Zhao","year":"2024","journal-title":"Heart Rhythm"},{"issue":"6","key":"10.1016\/j.cpcardiol.2025.103081_bib0136","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1007\/s00392-024-02389-3","article-title":"Efficacy of dapagliflozin in improving arrhythmia-related outcomes after ablation for atrial fibrillation: a retrospective single-center study","volume":"113","author":"Noh","year":"2024","journal-title":"Clin Res Cardiol"},{"issue":"11","key":"10.1016\/j.cpcardiol.2025.103081_bib0137","doi-asserted-by":"crossref","DOI":"10.1093\/europace\/euad333","article-title":"Rationale and design of a randomized trial of the dapagliflozin evaluation on atrial fibrillation patients followed Cox-Maze IV: the DETAIL-CMIV study","volume":"25","author":"Peng","year":"2023","journal-title":"EP Europace"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103081_bib0138","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1038\/s41467-017-01737-4","article-title":"Cardiac myocyte miR-29 promotes pathological remodeling of the heart by activating wnt signaling","volume":"8","author":"Sassi","year":"2017","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103081_bib0139","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1540-8159.2006.00298.x","article-title":"Suboptimal glycemic control, independently of QT interval duration, is associated with increased risk of ventricular arrhythmias in a high-risk population","volume":"29","author":"Chen-Scarabelli","year":"2006","journal-title":"Pacing Clin Electrophysiol"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103081_bib0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4239\/wjd.v12.i1.1","article-title":"Diabetes-induced changes in cardiac voltage-gated ion channels","volume":"12","author":"Ozturk","year":"2021","journal-title":"World J Diabetes"},{"issue":"5","key":"10.1016\/j.cpcardiol.2025.103081_bib0141","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1002\/ehf2.13553","article-title":"Acute pleiotropic effects of dapagliflozin in type 2 diabetic patients with heart failure with reduced ejection fraction: a crossover trial","volume":"8","author":"Ilyas","year":"2021","journal-title":"ESC Heart Fail"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103081_bib0142","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s12933-021-01293-8","article-title":"Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis","volume":"20","author":"Li","year":"2021","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"10.1016\/j.cpcardiol.2025.103081_bib0143","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.hrthm.2021.03.028","article-title":"Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: a meta-analysis of 34 randomized controlled trials","volume":"18","author":"Fernandes","year":"2021","journal-title":"Heart Rhythm"},{"issue":"5","key":"10.1016\/j.cpcardiol.2025.103081_bib0144","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1111\/jce.15894","article-title":"SGLT2 inhibitors reduce sudden cardiac death risk in heart failure: meta-analysis of randomized clinical trials","volume":"34","author":"Oates","year":"2023","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103081_bib0145","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1093\/europace\/euab177","article-title":"Association between sodium\u2013glucose cotransporter-2 inhibitors and risk of sudden cardiac death or ventricular arrhythmias: a meta-analysis of randomized controlled trials","volume":"24","author":"Sfairopoulos","year":"2021","journal-title":"EP Europace"},{"issue":"10","key":"10.1016\/j.cpcardiol.2025.103081_bib0146","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2400147","article-title":"Ertugliflozin to reduce arrhythmic burden in patients with ICDs\/CRT-Ds","volume":"3","author":"Benedikt","year":"2024","journal-title":"NEJM Evid"},{"key":"10.1016\/j.cpcardiol.2025.103081_bib0147","article-title":"Canagliflozin pretreatment attenuates myocardial dysfunction and improves postcardiac arrest outcomes after cardiac arrest and cardiopulmonary resuscitation in mice","author":"Ju","year":"2023","journal-title":"Cardiovasc Drugs Ther"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103081_bib0148","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s12933-021-01392-6","article-title":"Empagliflozin protects the heart against ischemia\/reperfusion-induced sudden cardiac death","volume":"20","author":"Hu","year":"2021","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"10.1016\/j.cpcardiol.2025.103081_bib0149","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/ehjcvp\/pvad033","article-title":"Sodium-glucose cotransporter-2 inhibitors compared with glucagon-like-peptide-1 receptor agonists and out-of-hospital cardiac arrest in type 2 diabetes: a nationwide nested case-control study","volume":"9","author":"J\u00fal\u00edusd\u00f3ttir","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103081_bib0150","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s10787-020-00732-4","article-title":"Empagliflozin suppresses inflammation and protects against acute septic renal injury","volume":"29","author":"Maayah","year":"2021","journal-title":"Inflammopharmacology"},{"issue":"8","key":"10.1016\/j.cpcardiol.2025.103081_bib0151","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1097\/CCM.0000000000005869","article-title":"Risk of ICU admission and related mortality in patients with sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase-4 inhibitors: a territory-wide retrospective cohort study","volume":"51","author":"Ng","year":"2023","journal-title":"Crit Care Med"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103081_bib0152","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s13054-023-04481-y","article-title":"Sodium glucose co-transporter-2 inhibitors in intensive care unit patients with type 2 diabetes: a pilot case control study","volume":"27","author":"M\u00e5rtensson","year":"2023","journal-title":"Critical Care"},{"issue":"5","key":"10.1016\/j.cpcardiol.2025.103081_bib0153","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1001\/jama.2024.10510","article-title":"Dapagliflozin for critically ill patients with acute organ dysfunction: the DEFENDER randomized clinical trial","volume":"332","author":"Tavares","year":"2024","journal-title":"Jama"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103081_bib0154","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrneph.2016.170","article-title":"metabolic and cardiovascular considerations of SGLT2 inhibition","volume":"13","author":"DeFronzo","year":"2017","journal-title":"Nat Rev Nephrol"},{"issue":"23","key":"10.1016\/j.cpcardiol.2025.103081_bib0155","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1042\/CS20201274","article-title":"SGLT2 inhibition versus sulfonylurea treatment effects on electrolyte and acid-base balance: secondary analysis of a clinical trial reaching glycemic equipoise: tubular effects of SGLT2 inhibition in type 2 diabetes","volume":"134","author":"van Bommel","year":"2020","journal-title":"Clin Sci (Lond)"},{"issue":"12","key":"10.1016\/j.cpcardiol.2025.103081_bib0156","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/s41574-019-0275-6","article-title":"SGLT2 inhibitors and urinary tract infections","volume":"15","author":"Wilding","year":"2019","journal-title":"Nat Rev Endocrinol"},{"issue":"9","key":"10.1016\/j.cpcardiol.2025.103081_bib0157","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1111\/dom.14075","article-title":"Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"22","author":"Liu","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"10.1016\/j.cpcardiol.2025.103081_bib0158","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1002\/ejhf.2681","article-title":"Renal effects of empagliflozin in patients hospitalized for acute heart failure: from the EMPULSE trial","volume":"24","author":"Voors","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"10.1016\/j.cpcardiol.2025.103081_bib0159","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.cpcardiol.2025.103081_bib0160","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-8587(18)30141-4","article-title":"Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials","volume":"6","author":"Perkovic","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103081_bib0161","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11892-021-01442-z","article-title":"Renal protection with SGLT2 inhibitors: effects in acute and chronic kidney disease","volume":"22","author":"Bailey","year":"2022","journal-title":"Curr Diab Rep"},{"issue":"4","key":"10.1016\/j.cpcardiol.2025.103081_bib0162","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1002\/ehf2.13955","article-title":"Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure","volume":"9","author":"Thiele","year":"2022","journal-title":"ESC Heart Fail"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103081_bib0163","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s13054-023-04481-y","article-title":"Sodium glucose co-transporter-2 inhibitors in intensive care unit patients with type 2 diabetes: a pilot case control study","volume":"27","author":"M\u00e5rtensson","year":"2023","journal-title":"Crit Care"},{"issue":"5","key":"10.1016\/j.cpcardiol.2025.103081_bib0164","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2023-003666","article-title":"Euglycemic diabetic ketoacidosis in the era of SGLT-2 inhibitors","volume":"11","author":"Chow","year":"2023","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"9","key":"10.1016\/j.cpcardiol.2025.103081_bib0165","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.2337\/dc15-0843","article-title":"Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition","volume":"38","author":"Peters","year":"2015","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.cpcardiol.2025.103081_bib0166","doi-asserted-by":"crossref","first-page":"978","DOI":"10.2337\/dc22-0885","article-title":"Distinct mechanisms responsible for the increase in glucose production and ketone formation caused by Empagliflozin in T2DM patients","volume":"46","author":"Abdelgani","year":"2023","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.cpcardiol.2025.103081_bib0167","doi-asserted-by":"crossref","DOI":"10.3390\/jpm14070665","article-title":"From sweet to sour: sGLT-2-inhibitor-induced euglycemic diabetic ketoacidosis","volume":"14","author":"Koceva","year":"2024","journal-title":"J Pers Med"},{"issue":"2","key":"10.1016\/j.cpcardiol.2025.103081_bib0168","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1172\/JCI70704","article-title":"Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production","volume":"124","author":"Merovci","year":"2014","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.cpcardiol.2025.103081_bib0169","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nm.3828","article-title":"Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion","volume":"21","author":"Bonner","year":"2015","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103081_bib0170","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/s12902-022-01126-z","article-title":"The effect of preoperative sodium-glucose cotransporter 2 inhibitors on the incidence of perioperative metabolic acidosis: a retrospective cohort study","volume":"22","author":"Iwasaki","year":"2022","journal-title":"BMC Endocr Disord"},{"issue":"3","key":"10.1016\/j.cpcardiol.2025.103081_bib0171","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00540-023-03174-8","article-title":"Sodium-glucose cotransporter 2 inhibitor-associated perioperative ketoacidosis: a systematic review of case reports","volume":"37","author":"Seki","year":"2023","journal-title":"J Anesth"},{"key":"10.1016\/j.cpcardiol.2025.103081_bib0172","unstructured":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022;400(10365):1788-801."},{"issue":"22","key":"10.1016\/j.cpcardiol.2025.103081_bib0173","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.cpcardiol.2025.103081_bib0174","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.cpcardiol.2025.103081_bib0175","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.cpcardiol.2025.103081_bib0176","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/dom.13648","article-title":"Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis","volume":"21","author":"Toyama","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103081_bib0177","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.pcd.2017.06.004","article-title":"Clinical risk factors predicting genital fungal infections with sodium-glucose cotransporter 2 inhibitor treatment: the ABCD nationwide dapagliflozin audit","volume":"12","author":"Thong","year":"2018","journal-title":"Prim Care Diabetes"},{"key":"10.1016\/j.cpcardiol.2025.103081_bib0178","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejim.2025.01.014","article-title":"Safety and efficacy of early initiation of sodium-glucose co-transporter inhibitors 2 in patients hospitalized for acute heart failure: a meta-analysis of randomized controlled trials","author":"Laborante","year":"2025","journal-title":"Eur J Intern Med"},{"issue":"6","key":"10.1016\/j.cpcardiol.2025.103081_bib0179","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.1002\/ehf2.14090","article-title":"Use of sodium glucose co-transporter 2 inhibitors in acute heart failure: a practical guidance","volume":"9","author":"Ferreira","year":"2022","journal-title":"ESC Heart Fail"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280625001033?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280625001033?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T15:55:17Z","timestamp":1751385317000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146280625001033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":179,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0146280625001033"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2025.103081","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early prescription of SGLT2i for acute patient care: from current evidence to future directions","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2025.103081","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103081"}}